New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...

It’s been long known that women with BRCA1 and BRCA2 gene mutations are at higher risk for breast and ovarian cancer. More ...

Precision medicine is an innovative approach that tailors treatment to the unique genetic and molecular characteristics of a ...

RISK-REDUCING surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Women who underwent bilateral mastectomy or removal of ovaries and Fallopian tubes had lower rates of recurrence, ovarian ...

After a median follow-up of 6.1 years, patients treated with Lynparza continued to show significant improvements in survival ...

"In BRCA carriers with prior diagnosis of breast cancer ... pointing out that BRCA1 mutation carriers mostly develop ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...